A Phase 2 interventional study of Cariprazine (RGH-188) and Placebo in Bipolar Disorder, sponsored by Forest Laboratories. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-14.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Bipolar Disorder by AbbVie — 2 open to participants now, 2 under way, none of them phase 3. Bipolar Disorder · AbbVie.
Among the 11 studies in Bipolar Disorder by AbbVie, this one is the 5th largest by enrollment, is the only one that started in 2007, is one of 6 in phase 2, and was the 2nd registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →2 of the 11 studies in Bipolar Disorder by AbbVie are open now, in 1 country. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 18–65
AbbVie · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 238 is above the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 234 across the 11 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
2 of the studies in Bipolar Disorder by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07071532AbbVieA Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder | 2027-02 |
| NCT06696755AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Bipolar Disorder by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study designed to evaluate the efficacy, safety, and tolerability of RGH-188 monotherapy in the treatment of acute mania. This study will be 5 weeks in duration; 3 weeks double-blind treatment and 2-weeks safety follow-up. All patients meeting the eligibility criteria will be randomized to one of two treatment groups: RGH-188 or placebo
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Having a total Young Mania Rating Scale (YMRS) score >= 20 and a score of at least 4 on two of the following YMRS items:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
Drug: Cariprazine (RGH-188)
Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
Drug: Placebo
Cariprazine 3 mg - 12 mg oral administration, once per day.
Dose-matched placebo oral administration, once per day.
Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3
The YMRS is an 11-item scale that assesses manic symptoms based on the participant's perception of his or her condition over the previous 48 hours, as well as the physician's clinical observations during the interview. The 11-items are elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, rate and amount of speech, language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. The severity of the abnormality for 7-items are rated on a five-point scale (0-4) and 4-items on a nine-point scale (0-8). The individual scores are summed for a total possible score of 0 (best) to 60 (worst). A negative change from Baseline indicates improvement. Analyses are based on an Analysis of Covariance (ANCOVA) model for change from Baseline with treatment group and study center as factors and Baseline value as covariate.
Time frame: Baseline, Week 3
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score at Week 3
The CGI-S measures the investigator's assessment of overall severity of the participant's illness compared with the severity of illness in other patients the physician has observed using a 7-point scale (1=Normal, not ill at all to 7=Among the most extremely ill participants). A negative change from Baseline indicates improvement. Analyses are based on ANCOVA model for change from Baseline with treatment group and study center as factors and Baseline CGI-S score as covariate.
Time frame: Baseline, 3 Weeks
| Milestone | Placebo | Cariprazine |
|---|---|---|
| Started | 120 | 118 |
| Safety population: received study drug | 118 | 118 |
| Completed | 73 | 75 |
| Not completed | 47 | 43 |
| Withdrew: Adverse event | 13 | 17 |
| Withdrew: Insufficient therapeutic response | 18 | 11 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Withdrawal of consent | 15 | 13 |
| Withdrew: Lost to follow-up | 1 | 0 |
The YMRS is an 11-item scale that assesses manic symptoms based on the participant's perception of his or her condition over the previous 48 hours, as well as the physician's clinical observations during the interview. The 11-items are elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, rate and amount of speech, language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. The severity of the abnormality for 7-items are rated on a five-point scale (0-4) and 4-items on a nine-point scale (0-8). The individual scores are summed for a total possible score of 0 (best) to 60 (worst). A negative change from Baseline indicates improvement. Analyses are based on an Analysis of Covariance (ANCOVA) model for change from Baseline with treatment group and study center as factors and Baseline value as covariate.
| score on a scale | Placebo | Cariprazine |
|---|---|---|
| Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3 | -8.91 ± 1.083 | -15.02 ± 1.078 |
The CGI-S measures the investigator's assessment of overall severity of the participant's illness compared with the severity of illness in other patients the physician has observed using a 7-point scale (1=Normal, not ill at all to 7=Among the most extremely ill participants). A negative change from Baseline indicates improvement. Analyses are based on ANCOVA model for change from Baseline with treatment group and study center as factors and Baseline CGI-S score as covariate.
| score on a scale | Placebo | Cariprazine |
|---|---|---|
| Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score at Week 3 | -0.93 ± 0.125 | -1.57 ± 0.125 |
Collected over First dose of study drug to 30 days past last dose (Up to 51 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 6/118 (5.1%) | 73/118 (61.9%) |
| Cariprazine | — | 7/118 (5.9%) | 90/118 (76.3%) |
| Event | Placebo | Cariprazine |
|---|---|---|
| ManiaPsychiatric disorders | 5/118 | 4/118 |
| ConvulsionNervous system disorders | 0/118 | 1/118 |
| Extrapyramidal disorderNervous system disorders | 0/118 | 1/118 |
| DelusionPsychiatric disorders | 1/118 | 0/118 |
| HypertensionVascular disorders | 1/118 | 0/118 |
| Deep vein thrombosisVascular disorders | 0/118 | 1/118 |
| Event | Placebo | Cariprazine |
|---|---|---|
| Extrapyramidal disorderNervous system disorders | 13/118 | 29/118 |
| HeadacheNervous system disorders | 26/118 | 24/118 |
| AkathisiaNervous system disorders | 8/118 | 23/118 |
| ConstipationGastrointestinal disorders | 10/118 | 19/118 |
| NauseaGastrointestinal disorders | 12/118 | 19/118 |
| DyspepsiaGastrointestinal disorders | 9/118 | 15/118 |
| DizzinessNervous system disorders | 8/118 | 12/118 |
| VomitingGastrointestinal disorders | 6/118 | 10/118 |
| InsomniaPsychiatric disorders | 3/118 | 10/118 |
| AgitationPsychiatric disorders | 10/118 | 6/118 |
Safety population included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | Cariprazine | Total |
|---|---|---|---|
| Mean | 38.7 ± 11.0 | 38.0 ± 10.3 | 38.3 ± 10.7 |
| Sex: Female, Male(Participants) | Placebo | Cariprazine | Total |
|---|---|---|---|
| Female | 41 | 38 | 79 |
| Male | 77 | 80 | 157 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Cariprazine | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 6 | 10 |
| Not Hispanic or Latino | 114 | 112 | 226 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Cariprazine | Total |
|---|---|---|---|
| Caucasian | 55 | 47 | 102 |
| Black | 31 | 36 | 67 |
| Asian | 28 | 30 | 58 |
| Other | 4 | 5 | 9 |
| Weight(kilogram (kg)) | Placebo | Cariprazine | Total |
|---|---|---|---|
| Mean | 79.3 ± 20.0 | 75.0 ± 20.3 | 77.2 ± 20.2 |
| Height(centimeter (cm)) | Placebo | Cariprazine | Total |
|---|---|---|---|
| Mean | 170.0 ± 10.4 | 169.9 ± 10.0 | 170.0 ± 10.2 |
| Body Mass Index (BMI)(kg/meter(m)^2) | Placebo | Cariprazine | Total |
|---|---|---|---|
| Mean | 27.2 ± 5.8 | 25.8 ± 5.9 | 26.5 ± 5.9 |
The record gives a start of Jun 2007, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 8 years 9 months after primary completion. A results delay was requested in Mar 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine